The FDA has issued a clinical hold on Amgen’s phase I trial of the experimental weight-loss drug AMG 513. In other news, Children’s Hospital Los Angeles has suspended the initiation of puberty blockers in transgender patients younger than 19 after an executive order from former President Trump. Defense Secretary Pete Hegseth has also directed the military to suspend the integration of new transgender recruits and to suspend medical treatment for troops with gender dysphoria.
The FDA approved mirdametinib (Gomekli) for adults and children 2 years and older with neurofibromatosis type 1 (NF1) and symptomatic plexiform neurofibromas (PN) that are not resectable surgically.
The article explores how artificial intelligence (AI) is transforming transdermal drug delivery systems (TDDS), offering innovative solutions to traditional challenges in drug administration. TDDS provides advantages over conventional oral and injectable methods by bypassing liver metabolism and enabling controlled drug release, but faces limitations due to the skin’s natural barrier properties.
The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™, a new antibiotic combination developed to treat complicated intra-abdominal infections caused by drug-resistant bacteria. This approval marks a significant step forward in combating antimicrobial resistance (AMR), a growing global health concern. EMBLAVEO™ is specifically designed to target bacteria that have become resistant to many existing antibiotics, offering a much-needed treatment option for patients facing limited choices in managing severe infections.
Diabetic emergencies remain a significant healthcare challenge in developing countries, presenting a complex intersection of medical, social, and economic issues. This systematic review highlights the concerning prevalence and impact of acute diabetic complications in resource-limited settings.
